Sanofi Collaborated with Teva to Co-Develop and Co-Commercialize TEV ‘574 for Inflammatory Bowel Disease
- Teva will receive a $500M up front, ~$1B in development & launch milestones. Both companies will equally share the development costs globally along with net profits & losses in major markets
- Sanofi will be responsible for the development of the P-III program & commercialization in North America, Japan, other parts of Asia & the rest of the world. Teva will lead the commercialization of the product in the EU, Israel & specified other countries
- The collaboration uses the innovative R&D & commercial expertise of both companies & supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases. TEV ‘574 is currently being studied in the P-IIb trials for UC & CD
Ref: Businesswire | Image: Teva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.